0001209191-20-052154.txt : 20200925 0001209191-20-052154.hdr.sgml : 20200925 20200925201307 ACCESSION NUMBER: 0001209191-20-052154 CONFORMED SUBMISSION TYPE: 4/A PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200922 FILED AS OF DATE: 20200925 DATE AS OF CHANGE: 20200925 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: EASTHAM KARIN CENTRAL INDEX KEY: 0001231845 FILING VALUES: FORM TYPE: 4/A SEC ACT: 1934 Act SEC FILE NUMBER: 000-24006 FILM NUMBER: 201201824 MAIL ADDRESS: STREET 1: C/O BURNHAM INSTITUTE FOR MEDICAL RESEAR STREET 2: 10901 N. TORREY PINES ROAD CITY: LA JOLLA STATE: CA ZIP: 92037 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: NEKTAR THERAPEUTICS CENTRAL INDEX KEY: 0000906709 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 943134940 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 455 MISSION BAY BOULEVARD SOUTH CITY: SAN FRANCISCO STATE: CA ZIP: 94158 BUSINESS PHONE: 4154825300 MAIL ADDRESS: STREET 1: 455 MISSION BAY BOULEVARD SOUTH CITY: SAN FRANCISCO STATE: CA ZIP: 94158 FORMER COMPANY: FORMER CONFORMED NAME: INHALE THERAPEUTIC SYSTEMS INC DATE OF NAME CHANGE: 19980723 FORMER COMPANY: FORMER CONFORMED NAME: INHALE THERAPEUTIC SYSTEMS DATE OF NAME CHANGE: 19940303 4/A 1 doc4a.xml FORM 4/A SUBMISSION X0306 4/A 2020-09-22 2020-09-24 0 0000906709 NEKTAR THERAPEUTICS NKTR 0001231845 EASTHAM KARIN C/O NEKTAR THERAPEUTICS 455 MISSION BAY BLVD SOUTH SAN FRANCISCO CA 94158 1 0 0 0 Common Stock 2020-09-22 4 A 0 9100 0.00 A 24100 D Stock Option 19.90 2020-09-22 4 A 0 18200 0.00 A 2028-09-21 Common Stock 18200 18200 D This stock award was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting of the unit, one share of the issuer's common stock. This restricted stock unit award vests in full, one year following September 22, 2020. This stock option vests in equal monthly installments over the one-year period beginning on September 22, 2020. This amendment is being filed solely to correct the exercise price previously reported for this option grant. All other information in the original Form 4 remains the same. Mark A. Wilson, Attorney-in-Fact 2020-09-25